The Association of Fecal Calprotectin and Respiratory Exacerbation in Cystic Fibrosis Patients

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2022 Nov 28

PMID 36443671

Authors

Farid Imanzadeh

Fatemeh Kerami

Maryam Hassanzad

Amirhossein Hosseini

Mahmoud Hajipour

Ghamartaj Khanbabaee

Naghi Dara

Katayoun Khatami

Nazanin Farahbakhsh

Aliakbar Sayyari

Affiliations

Soon will be listed here.

Abstract

Background: CF patients experience several episodes of pulmonary exacerbations and reduction in their lung function progressively. Lung function is not the only diagnostic index by physicians to decide if CF patients require antibiotic therapy following pulmonary exacerbations. Non-invasive fecal indicators are increasingly being used to assess intestinal inflammation. Calprotectin is the most extensively utilized fecal biomarker in recent CF researches.

Methods: In this longitudinal study, 30 CF patients (1-18 years) without current infectious gastroenteritis were recruited from Mofid Children's Hospital and Masih Daneshvari Hospital, Tehran, Iran. Then, fecal calprotectin levels were evaluated before treatment, two weeks after systemic antibiotic administration, as well as recurrence of pulmonary exacerbation after first post-hospital discharge.

Results: The initial fecal calprotectin level in CF patients receiving antibiotics was 651.13 ± 671.04, significantly decreasing two weeks after antibiotic therapy and following recurrence (171.81 ± 224.40, 607.93 ± 549.89, respectively; P < 0.01). Following systemic antibiotic treatment, the patient's respiratory and GI symptoms improved (P < 0.01).

Conclusion: Our findings revealed that fecal calprotectin modifications are associated with CF pulmonary exacerbations and antibiotic treatment could reduce calprotectin levels. Therefore, the fecal calprotectin level could be considered as a diagnostic tool and an index to follow the response to treatment in CF pulmonary exacerbations.

Citing Articles

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons.

Al-Beltagi M, Saeed N, Bediwy A, Elbeltagi R World J Clin Pediatr. 2024; 13(2):93341.

PMID: 38948001 PMC: 11212754. DOI: 10.5409/wjcp.v13.i2.93341.

References

Werlin S, Benuri-Silbiger I, Kerem E, Adler S, Goldin E, Zimmerman J . Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2010; 51(3):304-8. DOI: 10.1097/MPG.0b013e3181d1b013. View

Sanders D, Bittner R, Rosenfeld M, Hoffman L, Redding G, Goss C . Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010; 182(5):627-32. PMC: 5450763. DOI: 10.1164/rccm.200909-1421OC. View

Schnapp Z, Hartman C, Livnat G, Shteinberg M, Elenberg Y . Decreased Fecal Calprotectin Levels in Cystic Fibrosis Patients After Antibiotic Treatment for Respiratory Exacerbation. J Pediatr Gastroenterol Nutr. 2019; 68(2):282-284. DOI: 10.1097/MPG.0000000000002197. View

Goss C . Acute Pulmonary Exacerbations in Cystic Fibrosis. Semin Respir Crit Care Med. 2019; 40(6):792-803. PMC: 7528649. DOI: 10.1055/s-0039-1697975. View

Borowitz D, Gelfond D . Intestinal complications of cystic fibrosis. Curr Opin Pulm Med. 2013; 19(6):676-80. DOI: 10.1097/MCP.0b013e3283659ef2. View

Lord R, Jones A, Horsley A . Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev. 2020; 4:CD009529. PMC: 7117566. DOI: 10.1002/14651858.CD009529.pub4. View

Wagener J, Williams M, Millar S, Morgan W, Pasta D, Konstan M . Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. J Cyst Fibros. 2018; 17(4):496-502. DOI: 10.1016/j.jcf.2018.02.003. View

Bathe A, Mavropoulou E, Mechie N, Petzold G, Ellenrieder V, Kunsch S . Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. PLoS One. 2019; 14(10):e0223893. PMC: 6812761. DOI: 10.1371/journal.pone.0223893. View

Leung D, Heltshe S, Borowitz D, Gelfond D, Kloster M, Heubi J . Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life. JAMA Pediatr. 2017; 171(6):546-554. PMC: 5731827. DOI: 10.1001/jamapediatrics.2017.0206. View

10.

Dong K, Singh A, Ng R, Sin D, Tebbutt S, Ratjen F . Proteomic Profiling to Identify Blood Biomarkers Predictive of Response to Azithromycin in Children and Adolescents With Cystic Fibrosis. Chest. 2019; 156(4):667-673. DOI: 10.1016/j.chest.2019.05.017. View

11.

Waters V, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau Y . Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros. 2015; 14(6):755-62. DOI: 10.1016/j.jcf.2015.01.007. View

12.

Gelfond D, Borowitz D . Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol. 2012; 11(4):333-42. DOI: 10.1016/j.cgh.2012.11.006. View

13.

Horsley A, Davies J, Gray R, Macleod K, Donovan J, Aziz Z . Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax. 2013; 68(6):532-9. DOI: 10.1136/thoraxjnl-2012-202538. View

14.

Jung D, Dong K, Jang J, Lam G, Wilcox P, Quon B . Circulating CRP and calprotectin to diagnose CF pulmonary exacerbations. J Cyst Fibros. 2020; 20(1):46-49. DOI: 10.1016/j.jcf.2020.04.016. View

15.

Reid P, McAllister D, Boyd A, Innes J, Porteous D, Greening A . Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis. Am J Respir Crit Care Med. 2015; 191(2):233-6. PMC: 4347434. DOI: 10.1164/rccm.201407-1365LE. View

16.

Pathirana W, Chubb S, Gillett M, Vasikaran S . Faecal Calprotectin. Clin Biochem Rev. 2019; 39(3):77-90. PMC: 6370282. View

17.

VanDevanter D, Morris N, Konstan M . IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2015; 15(3):372-9. PMC: 4841746. DOI: 10.1016/j.jcf.2015.10.006. View

18.

Adriaanse M, van der Sande L, Van den Neucker A, Menheere P, Dompeling E, Buurman W . Evidence for a Cystic Fibrosis Enteropathy. PLoS One. 2015; 10(10):e0138062. PMC: 4617711. DOI: 10.1371/journal.pone.0138062. View

19.

Bodewes F, Verkade H, Wilschanski M . Gastroenterological endpoints in drug trials for cystic fibrosis. Pediatr Pulmonol. 2016; 51(S44):S18-S22. DOI: 10.1002/ppul.23528. View

20.

Garg M, Leach S, Coffey M, Katz T, Strachan R, Pang T . Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. J Cyst Fibros. 2017; 16(5):631-636. DOI: 10.1016/j.jcf.2017.03.010. View